ZYMUTEST™ HIA IgG

Enzyme Immuno-assay designed for measuring heparin-dependent antibodies of the IgG isotype, in human plasma. This assay measures only the IgG isotype, reported as the most associated with the clinical complications of heparin-dependent antibodies (HIT/HITT), allowing confirmation of the diagnosis of HIT/HITT or its clinical suspicion. However, some cases associated with only IgM and/or IgA isotypes can be missed.

Recent anecdotal evidence suggests a link between a prothrombotic state and people who have recently received a Covid vaccination. These prothrombotic states are being referred to as VATTS (vaccine-associated thrombosis/thrombocytopenia syndrome) or VIPIT (vaccine inducted prothrombotic immune thrombocytopenia). As these patients present with thrombocytopenia the diagnosis of HIT can be difficult. The ZYMUTEST™ HIA IgG ELISA has been shown to be one of the most reliable tests in identifying these individuals. Because of the design of the ZYMUTEST™ HIA IgG ELISA which uses protamine sulphate to bind the heparin and platelet factors to the micro-titre wells only patient antibodies that cause thrombocytopenia induced by heparin are detected, i.e. true hit.

ZYMUTEST™ HIA has a proven performance of many years and complies with the ISTH guidelines on HIT confirmation assays. The kits are complete with positive and negative controls, platelet lysate, wash buffer and 8 well strips. Offered in 2 formats either 12×8 wells or 4×8 wells both kits can be used for individual patient testing as the 8 well strip format can manage samples and controls thus minimising any wastage.

Overview

• CE marked kits compliant with ISTH guidelines on HIT testing
• IgG specific is one of the assays of choice for HIT confirmation
• Complete kits constructed for ease of use and economy
• 96 well and 32 well presentations for all laboratory sizes
• Manufactured to enhance binding of true HIT IgG antibodies
• Tried and tested kits available now